Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in a fireside chat as part of the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 10:30 a.m. ET. To access the live webcast of the presentation, ...